Brian is a cardiologist and genetic epidemiologist who was educated and trained at Harvard, Yale, Oxford and Cambridge Universities. He graduated from Yale Medical School and trained as a clinical investigator resident in Internal Medicine and as a special student in clinical epidemiology and genetic epidemiology as part of the Robert Wood Johnson Clinical Scholars Program at Yale. He then trained in cardiology and interventional cardiology at Harvard Medical School. While at Harvard, he also completed the Program in Clinical Effectiveness at Harvard School of Public Health, and was an NHLBI Cardiovascular (Genetic) Epidemiology Fellow at the Brigham and Women’s Hospital and Harvard Medical School. He then earned a business degree from the University of Cambridge, and a degree in evidence-based medicine with a focus on clinical trial design from the University of Oxford He is currently Professor and Director of Research in Translational Therapeutics, and Head of the Centre for Naturally Randomized Trials at the University of Cambridge, UK; and Visiting Professor in Cardiovascular Medicine at the University of Milan, Italy. Prior to his current post in Cambridge, his previous positions included Chief of Cardiology and Director of the Cardiovascular Genomic Research Centre at Wayne State University School of Medicine in the US; Chief Medical and Scientific Officer for a public-private collaboration working on the Chinese Precision Medicine Initiative in Beijing; and CEO of a biotechnology company. His research focuses on using Mendelian randomization to design ‘naturally randomized trials’ to generate naturally randomized evidence that can be used to improve the drug discovery and development process; inform the optimal design of randomized trials; fill evidence gaps when a randomized trial is not possible or practical; and define the practice of precision cardiovascular medicine.